• Above all, we make a difference.
  • Screening & Early Detection References


    1. Howlader N, Noone AM, Krapcho M, et al., editors. SEER Cancer Fast Stats, 1975-2013. National Cancer Institute: Bethesda, MD, http://seer.cancer.gov/csr/1975_2013/, 2016.
    2. Yaffe MJ, Mainprize JG. Risk of radiation-induced breast cancer from mammographic screening. Radiology. 258(1):98-105, 2011.
    3. de Gelder R, Draisma G, Heijnsdijk EA, de Koning HJ. Population-based mammography screening below age 50: balancing radiation-induced vs prevented breast cancer deaths. Br J Cancer. 104(7):1214-20, 2011.
    4. Miglioretti DL, Lange J, van den Broek JJ, et al. Radiation-induced breast cancer incidence and mortality from digital mammography screening: a modeling study. Ann Intern Med. 164(4):205-14, 2016.
    5. Gøtzsche PC, Jørgensen KJ. Screening for breast cancer with mammography. Cochrane Database Syst Rev. 6:CD001877, 2013.
    6. Sechopoulos I, Hendrick RE. Mammography and the risk of thyroid cancer. AJR Am J Roentgenol. 198(3):705-7, 2012.
    7. American Cancer Society. Cancer Prevention & Early Detection Facts & Figures, 2015-2016. American Cancer Society, 2015.
    8. Schell MJ, Yankaskas BC, Ballard-Barbash R, et al. Evidence-based target recall rates for screening mammography. Radiology. 243(3):681-9, 2007.
    9. Breast Cancer Surveillance Consortium (BCSC). Performance measures for 1,838,372 screening mammography examinations from 2004 to 2008 by age -- based on BCSC data through 2009. National Cancer Institute. http://breastscreening.cancer.gov/data/performance/screening/2009/perf_age.html, 2013.
    10. American Cancer Society. What does the doctor look for on a mammogram? http://www.cancer.org/treatment/understandingyourdiagnosis/examsandtestdescriptions/mammogramsandotherbreastimagingprocedures/mammograms-and-other-breast-imaging-procedures-what-does-doc-look-for, 2015.
    11. Canadian Cancer Society. Breast calcifications. https://www.cancer.ca/en/cancer-information/cancer-type/breast/breast-cancer/breast-calcifications/?region=on, 2016.
    12. D’Orsi CJ, Sickles EA, Mendelson EB, et al. ACR BI-RADS® Atlas, Breast Imaging Reporting and Data System. Reston, VA. American College of Radiology, 2013.
    13. American Cancer Society. Mammogram reports – BI-RADS. http://www.cancer.org/Treatment/UnderstandingYourDiagnosis/ExamsandTestDescriptions/MammogramsandOtherBreastImagingProcedures/mammograms-and-other-breast-imaging-procedures-mammo-report, 2015.
    14. American Cancer Society. American Cancer Society recommendations for early breast cancer detection in women without breast symptoms. http://www.cancer.org/cancer/breastcancer/moreinformation/breastcancerearlydetection/breast-cancer-early-detection-acs-recs, 2015.
    15. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology: Breast cancer screening and diagnosis, Version 1.2015. http://www.nccn.org, 2015.
    16. Siu AL on behalf of the U.S. Preventive Services Task Force. Screening for breast cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 164(4):279-96, 2016.
    17. Nelson HD, Fu R, Cantor A, Pappas M, Daeges M, Humphrey L. Effectiveness of breast cancer screening: systematic review and meta-analysis to update the 2009 U.S. Preventive Services Task Force Recommendation. Ann Intern Med. 164(4):244-55, 2016.
    18. Buist DS, Porter PL, Lehman C, Taplin SH, White E. Factors contributing to mammography failure in women aged 40-49 years. J Natl Cancer Inst. 96(19):1432-40, 2004.
    19. Qaseem A, Snow V, Sherif K, Aronson M, Weiss KB, Owens DK for the Clinical Efficacy Assessment Subcommittee of the American College of Physicians. Screening mammography for women 40 to 49 years of age: a clinical practice guideline from the American College of Physicians. Ann Intern Med. 146(7):511-5, 2007.
    20. Pace LE, He Y, Keating NL. Trends in mammography screening rates after publication of the 2009 US Preventive Services Task Force recommendations. Cancer. 119(14):2518-23, 2013.
    21. American Geriatrics Society. Breast cancer screening in older women. American Geriatrics Society Clinical Practice Committee. J Am Geriatr Soc. 48(7):842-4, 2000.
    22. Elmore JG, Barton MB, Moceri VM, et al. Ten-year risk of false positive screening mammograms and clinical breast examinations. N Engl J Med. 338: 1089-96, 1998.
    23. Hubbard RA, Kerlikowske K, Flowers CI, Yankaskas BC, Zhu W, Miglioretti DL. Cumulative probability of false-positive recall or biopsy recommendation after 10 years of screening mammography: a cohort study. Ann Intern Med. 155(8):481-92, 2011.
    24. Independent UK Panel on Breast Cancer Screening. The benefits and harms of breast cancer screening: an independent review. Lancet. 380(9855):1778-86, 2012.
    25. Kerlikowske K, Zhu W, Hubbard RA, et al. for the Breast Cancer Surveillance Consortium. Outcomes of screening mammography by frequency, breast density, and postmenopausal hormone therapy. JAMA Intern Med. 173(9):807-16, 2013.
    26. Tosteson AN, Fryback DG, Hammond CS, et al. Consequences of false-positive screening mammograms. JAMA Intern Med. 174(6):954-61, 2014.
    27. Rossouw JE, Anderson GL, Prentice RL, et al. for the Women's Health Initiative (WHI) Investigators Writing Group. Risk and benefits of estrogen plus progestin in health postmenopausal women: Principal results from the Women's Health Initiative Randomized Controlled Trial. JAMA. 288(3):321-33, 2002.
    28. U.S. Food and Drug Administration. Menopause and hormones: common questions. http://www.fda.gov/forconsumers/byaudience/forwomen/ucm118624.htm, 2014.
    29. Chlebowski RT, Hendrix SL, Langer RD, et al. for the Women's Health Initiative Investigators. Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women's Health Initiative Randomized Trial. JAMA. 289(24):3243-53, 2003.
    30. Chlebowski RT, Anderson G, Manson JE, et al. Estrogen alone in postmenopausal women and breast cancer detection by means of mammography and breast biopsy. J Clin Oncol. 28(16):2690-7, 2010.
    31. McTiernan A, Martin CF, Peck JD, et al. for the Women's Health Initiative Mammogram Density Study Investigators. Estrogen-plus-progestin use and mammographic density in postmenopausal women: women's health initiative randomized trial. J Natl Cancer Inst. 97(18):1366-76, 2005.
    32. Stefanick ML, Anderson GL, Margolis KL, et al. for the Women's Health Initiative Investigators. Effects of conjugated equine estrogens on breast cancer and mammography screening in postmenopausal women with hysterectomy. JAMA. 295(14):1647-57, 2006.
    33. McTiernan A, Chlebowski RT, Martin C, et al. for the Women's Health Initiative Investigators. Conjugated equine estrogen influence on mammographic density in postmenopausal women in a substudy of the women's health initiative randomized trial. J Clin Oncol. 27(36):6135-43, 2009.
    34. Buist DS, Anderson ML, Haneuse SJ, et al. Influence of annual interpretive volume on screening mammography performance in the United States. Radiology. 259(1):72-84, 2011.
    35. Rawashdeh MA, Lee WB, Bourne RM, et al. Markers of good performance in mammography depend on number of annual readings. Radiology. 269(1):61-7, 2013.
    36. Théberge I, Chang SL, Vandal N, et al. Radiologist interpretive volume and breast cancer screening accuracy in a Canadian organized screening program. J Natl Cancer Inst. 106(3):djt461, 2014.
    37. Taplin S, Abraham L, Barlow WE, et al. Mammography facility characteristics associated with interpretive accuracy of screening mammography. J Natl Cancer Inst. 100(12):876-87, 2008.
    38. Lee CS, Bhargavan-Chatfield M, Burnside ES, Nagy P, Sickles EA. The National Mammography Database: preliminary data. AJR Am J Roentgenol. 206(4):883-90, 2016.
    39. Oestreicher N, Lehman CD, Seger DJ, Buist DS, White E. The incremental contribution of clinical breast examination to invasive cancer detection in a mammography screening program. AJR Am J Roentgenol. 184(2):428-32, 2005.
    40. American Cancer Society. Cancer Facts and Figures 2016. Atlanta, GA: American Cancer Society, 2016.
    41. Van Zee KJ, White J, Morrow M, Harris JR. Chapter 23: Ductal carcinoma in situ and microinvasive carcinoma, in Harris JR, Lippman ME, Morrow M, Osborne CK. Diseases of the Breast, 5th edition. Lippincott Williams and Wilkins, 2014.
    42. Chiarelli AM, Majpruz V, Brown P, Thriault M, Shumak R, Mai V. The contribution of clinical breast examination to the accuracy of breast screening. J Natl Cancer Inst. 101(18):1236-43, 2009.
    43. Centers for Disease Control and Prevention. What are the symptoms of breast cancer? Atlanta, GA, Centers for Disease Control and Prevention. http://www.cdc.gov/cancer/breast/basic_info/symptoms.htm, 2016.
    44. National Cancer Institute. Breast cancer treatment: general information about breast cancer. http://www.cancer.gov/types/breast/patient/breast-treatment-pdq#section/_125, 2016.
    45. Kosters JP, Gotzsche PC. Regular self-examination or clinical examination for early detection of breast cancer (review). Cochrane Database Syst Rev. Issue 3: CD003373, 2008.
    46. Saslow D, Boetes C, Burke W, et al. for the American Cancer Society Breast Cancer Advisory Group. American Cancer Society guidelines for breast screening with MRI as an adjunct to mammography. CA Cancer J Clin. 57(2):75-89, 2007.
    47. Warner E, Messersmith H, Causer P, Eisen A, Shumak R, Plewes D. Systematic review: using magnetic resonance imaging to screen women at high risk for breast cancer. Ann Intern Med. 148(9):671-9, 2008.
    48. Chiarelli AM, Prummel MV, Muradali D, et al. Effectiveness of screening with annual magnetic resonance imaging and mammography: results of the initial screen from the Ontario High Risk Breast Screening Program. J Clin Oncol. 32(21):2224-30, 2014.
    49. Berg WA, Zhang Z, Lehrer D, et al. for the ACRIN 6666 Investigators. Detection of breast cancer with addition of annual screening ultrasound or a single screening MRI to mammography in women with elevated breast cancer risk. JAMA. 307(13):1394-404, 2012.
    50. Melnikow J, Fenton JJ, Whitlock EP, et al. Supplemental screening for breast cancer in women with dense breasts: a systematic review for the U.S. Preventive Services Task Force. Ann Intern Med. 164(4):268-78, 2016.
    51. Jain S and Gradishar WJ. Chapter 61: Male Breast Cancer. In Harris JR, Lippman ME, Morrow M, Osborne CK. Diseases of the Breast, 5th edition. Lippincott, Williams and Wilkins, 2014.
    52. American Cancer Society. Signs and symptoms of breast cancer in men. http://www.cancer.org/cancer/breastcancerinmen/detailedguide/breast-cancer-in-men-signs-symptoms, 2016.
    53. Liede A, Karlan BY, Narod SA. Cancer risks for male carriers of germline mutations in BRCA1 or BRCA2: a review of the literature. J Clin Oncol. 22(4):735-42, 2004.
    54. Tai YC, Domchek S, Parmigiani G, Chen S. Breast cancer risk among male BRCA1 and BRCA2 mutation carriers. J Natl Cancer Inst. 99(23):1811-4, 2007.
    55. Thorlacius S, Sigurdsson S, Bjarnadottir H, et al. Study of a single BRCA2 mutation with high carrier frequency in a small population. Am J Hum Genet. 60(5): 1079–1084, 1997.
    56. Orr N, Lemnrau A, Cooke R, et al. Genome-wide association study identifies a common variant in RAD51B associated with male breast cancer risk. Nat Genet. 44(11):1182-4, 2012.
    57. Lehman CD, Gatsonis C, Kuhl CK, et al. for the ACRIN Trial 6667 Investigators Group. MRI evaluation of the contralateral breast in women with recently diagnosed breast cancer. N Engl J Med. 356(13):1295-303, 2007.
    58. Bernard JR Jr, Vallow LA, DePeri ER, et al. In newly diagnosed breast cancer, screening MRI of the contralateral breast detects mammographically occult cancer, even in elderly women: the Mayo Clinic in Florida experience. Breast J. 16(2):118-26, 2010.
    59. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology: Breast cancer treatment, Version 2.2016. http://www.nccn.org, 2016.
    60. Pinsky RW, Helvie MA. Mammographic breast density: effect on imaging and breast cancer risk. J Natl Compr Canc Netw. 8(10):1157-64, 2010.
    61. O'Flynn EA, Ledger AE, deSouza NM. Alternative screening for dense breasts: MRI. AJR Am J Roentgenol. 204(2):W141-9, 2015.
    62. Melnikow J, Fenton JJ, Whitlock EP, et al. Supplemental screening for breast cancer in women with dense breasts: a systematic review for the U.S. Preventive Services Task Force. Ann Intern Med. 164(4):268-78, 2016.
    63. Gartlehner G, Thaler K, Chapman A, et al. Mammography in combination with breast ultrasonography versus mammography for breast cancer screening in women at average risk. Cochrane Database Syst Rev. 4:CD009632, 2013.
    64. Scheel JR, Lee JM, Sprague BL, Lee CI, Lehman CD. Screening ultrasound as an adjunct to mammography in women with mammographically dense breasts. Am J Obstet Gynecol. 212(1):9-17. 2015.
    65. Tagliafico AS, Calabrese M, Mariscotti G, et al. Adjunct screening with tomosynthesis or ultrasound in women with mammography-negative dense breasts: interim report of a Prospective comparative trial. J Clin Oncol. 2016 Mar 9. [Epub ahead of print].
    66. Riedl CC, Luft N, Bernhart C, et al. Triple-modality screening trial for familial breast cancer underlines the importance of magnetic resonance imaging and questions the role of mammography and ultrasound regardless of patient mutation status, age, and breast density. J Clin Oncol. 33(10):1128-35, 2015.
    67. Hendrick RE. Radiation doses and cancer risks from breast imaging studies. Radiology. 257(1):246-53, 2010.
    68. Skaane P, Bandos AI, Gullien R, et al. Comparison of digital mammography alone and digital mammography plus tomosynthesis in a population-based screening program. Radiology. 267(1):47-56, 2013.
    69. Bernardi D, Macaskill P, Pellegrini M, et al. Breast cancer screening with tomosynthesis (3D mammography) with acquired or synthetic 2D mammography compared with 2D mammography alone (STORM-2): a population-based prospective study. Lancet Oncol. 17(8):1105-13, 2016. 
    70. Friedewald SM, Rafferty EA, Rose SL, et al. Breast cancer screening using tomosynthesis in combination with digital mammography. JAMA. 311(24):2499-2507, 2014.
    71. Shermis RB, Wilson KD, Doyle MT, et al. Supplemental breast cancer screening with molecular breast imaging for women with dense breast tissue. AJR Am J Roentgenol. 207(2):450-7, 2016.
    72. Mainiero MB, Lourenco A, Mahoney MC, et al. ACR Appropriateness Criteria Breast Cancer Screening. J Am Coll Radiol. 10(1):11-4, 2013.
    73. Rhodes DJ, Hruska CB, Conners AL, et al. Journal Club: Molecular breast imaging at reduced radiation dose for supplemental screening in mammographically dense breasts. AJR Am J Roentgenol. 204(2):241-51, 2015.
    74. Lee CI and Elmore JC. Chapter 11. Breast Cancer Screening, in Harris JR, Lippman ME, Morrow M, Osborne CK. Diseases of the Breast, 5th edition. Lippincott Williams and Wilkins, 2014.
    75. U.S. Food and Drug Administration (FDA). FDA Safety Communication: Breast cancer screening - Thermography is not an alternative to mammography. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm257633.htm, 2011.
    76. Duric N, Boyd N, Littrup P, et al. Breast density measurements with ultrasound tomography: a comparison with film and digital mammography. Med Phys. 40(1):013501, 2013.
    77. Miranda PY, Tarraf W, Gonzlez HM. Breast cancer screening and ethnicity in the United States: implications for health disparities research. Breast Cancer Res Treat. 128(2):535-42, 2011.
    78. Watson-Johnson LC, DeGroff A, Steele CB, et al. Mammography adherence: a qualitative study. J Womens Health (Larchmt). 20(12):1887-94, 2011.
    79. Plescia M, White MC. The National Prevention Strategy and breast cancer screening: scientific evidence for public health action. Am J Public Health. 103(9):1545-8, 2013.
    80. Fayanju OM, Kraenzle S, Drake BF, Oka M, Goodman MS. Perceived barriers to mammography among underserved women in a Breast Health Center Outreach Program. Am J Surg. 208(3):425-34, 2014.
    81. Ramachandran A, Snyder FR, Katz ML, et al. for the Patient Navigation Research Program Investigators. Barriers to health care contribute to delays in follow-up among women with abnormal cancer screening: data from the Patient Navigation Research Program. Cancer. 121(22):4016-24, 2015.
    82. American Cancer Society. Breast Cancer Facts & Figures, 2015-2016. American Cancer Society, 2015.
    83. American Cancer Society. Cancer Facts and Figures 2016. Atlanta, GA: American Cancer Society, 2016.
    84. American Cancer Society. Cancer Facts and Figures for African Americans 2016-2018. Atlanta, GA: American Cancer Society, 2016.
    85. Smigal C, Jemal A, Ward E, et al. Trends in breast cancer by race and ethnicity: update 2006. CA Cancer J Clin. 56(3):168-83, 2006.
    86. Battaglia TA, Santana MC, Bak S, et al. Predictors of timely follow-up after abnormal cancer screening among women seeking care at urban community health centers. Cancer. 116(4):913-21, 2010.
    87. Warner ET, Tamimi RM, Hughes ME, et al. Time to diagnosis and breast cancer stage by race/ethnicity. Breast Cancer Res Treat. 136(3):813-21, 2012.
    88. George P, Chandwani S, Gabel M, et al. Diagnosis and surgical delays in African American and white women with early-stage breast cancer. J Womens Health (Larchmt). 24(3):209-17, 2015.
    89. Newman LA, Griffith KA, Jatoi I, Simon MS, Crowe JP, Colditz GA. Meta-analysis of survival in African American and white American patients with breast cancer: ethnicity compared with socioeconomic status. J Clin Oncol. 20;24(9):1342-9, 2006.
    90. Curtis E, Quale C, Haggstrom D, Smith-Bindman R. Racial and ethnic differences in breast cancer survival: how much is explained by screening, tumor severity, biology, treatment, comorbidities, and demographics? Cancer. 112(1):171-80, 2008.
    91. Centers for Disease Control and Prevention (CDC). Vital signs: racial disparities in breast cancer severity--United States, 2005-2009. MMWR Morb Mortal Wkly Rep. 61(45):922-6, 2012.
    92. Chen L, Li CI. Racial disparities in breast cancer diagnosis and treatment by hormone receptor and HER2 status. Cancer Epidemiol Biomarkers Prev. 24(11):1666-72, 2015.
    93. Iqbal J, Ginsburg O, Rochon PA, Sun P, Narod SA. Differences in breast cancer stage at diagnosis and cancer-specific survival by race and ethnicity in the United States. JAMA. 313(2):165-73, 2015.
    94. Warner ET, Tamimi RM, Boggs DA, et al. Estrogen receptor positive tumors: do reproductive factors explain differences in incidence between black and white women? Cancer Causes Control. 24(4):731-9, 2013.
    95. Batina NG, Trentham-Dietz A, Gangnon RE, et al. Variation in tumor natural history contributes to racial disparities in breast cancer stage at diagnosis. Breast Cancer Res Treat. 138(2):519-28, 2013.
    96. Warner ET, Tamimi RM, Hughes ME, et al. Racial and ethnic differences in breast cancer survival: mediating effect of tumor characteristics and sociodemographic and treatment factors. J Clin Oncol. 33(20):2254-61, 2015.
    97. Towne SD Jr, Smith ML, Ory MG. Geographic variations in access and utilization of cancer screening services: examining disparities among American Indian and Alaska Native Elders. Int J Health Geogr. 13:18, 2014.
    98. White A, Richardson LC, Li C, Ekwueme DU, Kaur JS. Breast cancer mortality among American Indian and Alaska Native women, 1990-2009. Am J Public Health. 104 Suppl 3:S432-8, 2014.
    99. American Cancer Society. Cancer Facts & Figures for Hispanics/Latinos, 2015-2017. American Cancer Society, 2015.
    100. Austin SB, Pazaris MJ, Nichols LP, Bowen D, Wei EK, Spiegelman D. An examination of sexual orientation group patterns in mammographic and colorectal screening in a cohort of U.S. women. Cancer Causes Control. 24(3):539-47, 2013.
    101. Hart SL, Bowen DJ. Sexual orientation and intentions to obtain breast cancer screening. J Womens Health (Larchmt). 18(2):177-85, 2009.
    102. Horner-Johnson W, Dobbertin K, Andresen EM, Iezzoni LI. Breast and cervical cancer screening disparities associated with disability severity. Womens Health Issues. 24(1):e147-53, 2014.
    103. Centers for Disease Control and Prevention. Women with disabilities and breast cancer screening. http://www.cdc.gov/ncbddd/disabilityandhealth/breast-cancer-screening.html, 2016.
    104. Courtney-Long E, Armour B, Frammartino B, Miller J. Factors associated with self-reported mammography use for women with and women without a disability. J Womens Health (Larchmt). 20(9):1279-86, 2011.
    105. Yankaskas BC, Dickens P, Bowling JM, et al. Barriers to adherence to screening mammography among women with disabilities. Am J Public Health. 100(5):947-53, 2010.
    106. Ramjan L, Cotton A, Algoso M, Peters K. Barriers to breast and cervical cancer screening for women with physical disability: a review. Women Health. 56(2):141-56, 2016.
    107. Clark MA, Rogers ML, Wen X, et al. Repeat mammography screening among unmarried women with and without a disability. Womens Health Issues. 19(6):415-24, 2009.
    108. Centers for Disease Control and Prevention. Women with disabilities. http://www.cdc.gov/ncbddd/disabilityandhealth/women.html, 2016.
    109. Alexandraki I, Mooradian AD. Barriers related to mammography use for breast cancer screening among minority women. J Natl Med Assoc. 102(3):206-18, 2010.
    110. Ballew C, Cummings SJ, Oreskovich J. Reported barriers to cancer screening: Montana Behavioral Risk Factor Surveillance System 2007. Am J Health Promot. 24(5):311-4, 2010.  
    111. Howlader N, Noone AM, Krapcho M, et al. (editors). SEER Cancer Statistics Review, 1975-2013. Table 1.12. National Cancer Institute. Bethesda, MD, http://seer.cancer.gov/csr/1975_2013/, 2016.

    Updated 11/08/16


    Screening and Early Detection Home





1-877 GO KOMEN